AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
Intrinsic Value
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. [ Read More ]
The intrinsic value of one
ACRX
stock under the Base Case scenario is
0.1484
USD.
Compared to the current market price of 1.1277 USD,
AcelRx Pharmaceuticals Inc
is
Overvalued by 87%.
ACRX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ACRX or that its price is influenced by factors unrelated to fundamentals.
AcelRx Pharmaceuticals Inc's market capitalization is 19.2m USD.
ACRX stock price is 1.1277 USD.
ACRX stock (0.1484 USD) is 87% less than its price (1.1277 USD).
ACRX. Open DCF Valuation
ACRX stock (0.1484 USD) is 87% less than its price (1.1277 USD). Open Relative Valuation
ACRX has upside potential of 311% compared to the average analyst price target.
Open Wall St Estimates
ACRX's ROE (Return on Equity) has significantly decreased in the last 3 years from 81% to -116%.
ACRX's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -180% to -102%, and is approaching profitability.
ACRX has negative Operating Income for the last twelve months.
ACRX has negative Net Income for the last twelve months.
ACRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -116%.
ACRX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -102%.
ACRX has negative Free Cash Flow for the last twelve months.
ACRX's Revenue has been falling by 51% per year for the last 3 years.
ACRX has negative three-year average ROE (Return on Equity): -295%. The company is not efficient at transforming stockholders' equity into net income.
ACRX has negative three-year average ROIC (Return on Invested Capital): -142%. The company is not efficient at using invested capital to generate operating income.
ACRX's short-term assets (14m USD) exceed its short-term liabilties (4m USD).
ACRX's long-term assets (23m USD) exceed its long-term liabilties (5m USD).
ACRX's D/E (Debt to Equity) is very low and is equal to 0.
ACRX's Altman Z-Score is very low and is equal to -28.18.
Valuation Backtest
AcelRx Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
ACRX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
AcelRx Pharmaceuticals Inc
Balance Sheet Decomposition
AcelRx Pharmaceuticals Inc
| Current Assets | 14.4m |
| Cash & Short-Term Investments | 13.4m |
| Other Current Assets | 1m |
| Non-Current Assets | 8.9m |
| Intangibles | 8.8m |
| Other Non-Current Assets | 100k |
| Current Liabilities | 3.6m |
| Accounts Payable | 1m |
| Accrued Liabilities | 1.8m |
| Other Current Liabilities | 800k |
| Non-Current Liabilities | 1.4m |
| Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
AcelRx Pharmaceuticals Inc
|
Revenue
|
620k
USD
|
|
Operating Expenses
|
-20.6m
USD
|
|
Operating Income
|
-20m
USD
|
|
Other Expenses
|
-6.5m
USD
|
|
Net Income
|
-26.5m
USD
|
Free Cash Flow Analysis
AcelRx Pharmaceuticals Inc
What is Free Cash Flow?
ACRX Profitability Score
Profitability Due Diligence
AcelRx Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
AcelRx Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
ACRX Solvency Score
Solvency Due Diligence
AcelRx Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
AcelRx Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACRX Price Targets Summary
AcelRx Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ACRX
is 4.63 USD
.
Ownership
ACRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ACRX Price
AcelRx Pharmaceuticals Inc
| Average Annual Return | -53% |
| Standard Deviation of Annual Returns | 19.96% |
| Max Drawdown | -99% |
| Market Capitalization | 19.2m USD |
| Shares Outstanding | 16 952 300 |
| Percentage of Shares Shorted | 3.75% |
Company Profile
AcelRx Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.
Contact
IPO
Employees
Officers
The intrinsic value of one
ACRX
stock under the Base Case scenario is
0.1484
USD.
Compared to the current market price of 1.1277 USD,
AcelRx Pharmaceuticals Inc
is
Overvalued by 87%.
You don't have any saved screeners yet
